Adagio Therapeutics, Inc. (Nasdaq: ADGI) announced its participation in several upcoming investor conferences. Management will engage in fireside chat discussions at the Stifel 2021 Virtual Healthcare Conference on November 16, and at the Jefferies 2021 Virtual London Healthcare Conference from November 16-19. Also, a fireside chat is scheduled for the Evercore ISI 4th Annual HealthconX Conference on December 1, 2021. Webcasts will be available on the company's investor website for 60 days post-presentation. Adagio focuses on developing antibody-based solutions for infectious diseases, including COVID-19.
Adagio Therapeutics (Nasdaq: ADGI) presented new in vitro data at the 2021 ISIRV-WHO Virtual Conference, showing its monoclonal antibody ADG20 retains potent neutralizing activity against various SARS-CoV-2 variants, including Lambda and Mu. These findings highlight ADG20's potential to combat ongoing COVID-19 challenges. Adagio is advancing two Phase 2/3 trials for ADG20 and plans to submit an EUA application to the FDA in Q1 2022. The antibody is engineered for broad neutralization and long-lasting protection.
Adagio Therapeutics (Nasdaq: ADGI) will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Disease Conference on Oct. 6, 2021, at 1:30 p.m. ET. The event will be streamed live on the investor section of their website and archived for 60 days. Adagio focuses on developing antibody-based solutions for infectious diseases with pandemic potential. Their antibody portfolio, including ADG20, aims to offer broad neutralization against SARS-CoV-2, enhanced manufacturability, and affordability.
Adagio Therapeutics (ADGI) announced promising updates on its COVID-19 antibody, ADG20, following ongoing Phase 1 studies showing a prolonged half-life of nearly 100 days and strong serum virus neutralization activity maintained over six months. Data from these studies support the 300 mg intramuscular dose, which is being evaluated in Phase 2/3 trials for treatment and prevention of COVID-19, aiming for Emergency Use Authorization in early 2022. The trial demonstrates ADG20’s potential with no related adverse events reported, as presented at IDWeek 2021 and the Discovery on Target Conference.